If you or a loved one has taken Reglan (metoclopramide) and noticed unusual, involuntary movements, you may be concerned about tardive dyskinesia. Building on decades of pharmacovigilance research, this page provides a clinical update on the signs to watch for, the latest FDA warnings, and what the science says about risk factors and monitoring.
Reglan (metoclopramide) is a medication approved for treating diabetic gastroparesis and symptomatic gastroesophageal reflux. However, its use carries a significant risk of causing tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning highlighting this risk, emphasizing that the likelihood of developing TD increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning is based on clinical evidence and postmarketing surveillance data. Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after Reglan is discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can be masked by metoclopramide itself, which may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates early detection and underscores the need for careful monitoring.
The FDA Adverse Event Reporting System (FAERS) database lists tardive dyskinesia as the most frequently reported adverse event associated with Reglan, with 5,712 reports (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN). Other movement-related disorders, such as extrapyramidal disorder (3,268 reports), dystonia (2,351 reports), and dyskinesia (779 reports), are also commonly reported. These data highlight the prevalence of neurological adverse effects linked to Reglan use. The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist. By blocking dopamine D2 receptors in the brain, metoclopramide can disrupt normal motor control, leading to the development of TD. This mechanism is similar to that of antipsychotic drugs, which are also known to cause TD. The risk is dose-dependent and cumulative, meaning that prolonged exposure increases the likelihood of developing the condition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The timeline between Reglan exposure and documented harm varies. TD can develop after weeks, months, or years of treatment, and symptoms may appear during therapy or after discontinuation. The FDA advises using Reglan for the shortest duration necessary and reassessing the need for continued treatment periodically (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the maximum recommended treatment duration is 12 weeks, though longer use may be unavoidable in some cases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If longer-term therapy is necessary, routine monitoring for signs and symptoms of TD is essential (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Causation considerations for affected patients are complex. While Reglan is a known cause of TD, other factors such as individual susceptibility, concurrent use of other drugs that can cause TD, and pre-existing neurological conditions may influence risk. The FDA warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is also contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, immediate discontinuation of Reglan is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
The adequacy of warnings regarding Reglan and TD has been addressed through FDA-mandated labeling. The boxed warning clearly states the risk of TD, the importance of using the shortest treatment duration, and the need for periodic reassessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warnings and precautions section further details the potential for irreversible movements and the need for immediate medical attention if symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, the high number of FAERS reports suggests that TD remains a significant clinical concern, possibly due to prolonged use or inadequate monitoring. In summary, Reglan is associated with a well-documented risk of tardive dyskinesia, a serious and potentially irreversible movement disorder. The risk increases with treatment duration and cumulative dose. Patients and healthcare providers should be vigilant for early signs of TD and adhere to recommended treatment limits. The FDA's warnings provide essential guidance, but the persistence of adverse events highlights the need for careful risk-benefit assessment in each case.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA issued a boxed warning for Reglan (metoclopramide) stating that the risk of developing tardive dyskinesia (TD) increases with longer treatment duration and higher cumulative doses. TD is a potentially irreversible movement disorder characterized by involuntary movements. The warning emphasizes using the shortest treatment duration necessary and periodic reassessment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Reglan (metoclopramide) causes tardive dyskinesia by blocking dopamine D2 receptors in the brain, disrupting normal motor control. This mechanism is similar to that of antipsychotic drugs. The risk is dose-dependent and cumulative, meaning prolonged exposure increases the likelihood of developing TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Symptoms of tardive dyskinesia include involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after Reglan is discontinued. The condition can be masked by metoclopramide itself, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
According to the FDA Adverse Event Reporting System (FAERS), tardive dyskinesia is the most frequently reported adverse event associated with Reglan, with 5,712 reports. Other movement disorders such as extrapyramidal disorder (3,268 reports), dystonia (2,351 reports), and dyskinesia (779 reports) are also commonly reported (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:REGLAN).
If signs or symptoms of tardive dyskinesia develop, immediate discontinuation of Reglan is recommended. You should contact your healthcare provider promptly. The FDA advises against using Reglan in patients with a history of TD and warns against concomitant use with other drugs that can cause TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.